CA3036313A1 - Compositions comprising a cannabinoid receptor binding ligand - Google Patents
Compositions comprising a cannabinoid receptor binding ligand Download PDFInfo
- Publication number
- CA3036313A1 CA3036313A1 CA3036313A CA3036313A CA3036313A1 CA 3036313 A1 CA3036313 A1 CA 3036313A1 CA 3036313 A CA3036313 A CA 3036313A CA 3036313 A CA3036313 A CA 3036313A CA 3036313 A1 CA3036313 A1 CA 3036313A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- thc
- composition according
- cannabinoid receptor
- receptor binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000018208 Cannabinoid Receptor Human genes 0.000 title claims abstract description 49
- 108050007331 Cannabinoid receptor Proteins 0.000 title claims abstract description 49
- 239000003446 ligand Substances 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims description 90
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 80
- 150000001335 aliphatic alkanes Chemical class 0.000 claims abstract description 37
- 239000007788 liquid Substances 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 15
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 138
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 137
- 229960004242 dronabinol Drugs 0.000 claims description 106
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 51
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 31
- 206010013774 Dry eye Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 210000004087 cornea Anatomy 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000028389 Nerve injury Diseases 0.000 claims description 11
- 210000000795 conjunctiva Anatomy 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000008764 nerve damage Effects 0.000 claims description 11
- 238000011200 topical administration Methods 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 8
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 7
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 210000000744 eyelid Anatomy 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 4
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 4
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000003981 vehicle Substances 0.000 description 32
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 30
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 27
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 27
- 229950011318 cannabidiol Drugs 0.000 description 27
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 230000004489 tear production Effects 0.000 description 25
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 15
- -1 ciclosporin A Chemical compound 0.000 description 14
- 210000005036 nerve Anatomy 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- CFMRIVODIXTERW-BHIFYINESA-N [(1r,2r,5r)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol Chemical compound COC1=CC(C(C)(C)CCCCCC)=CC(OC)=C1[C@H]1[C@H](C2(C)C)C[C@H]2C(CO)=C1 CFMRIVODIXTERW-BHIFYINESA-N 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000004215 Carbon black (E152) Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 229930195733 hydrocarbon Natural products 0.000 description 10
- 150000002430 hydrocarbons Chemical class 0.000 description 10
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 description 9
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 description 8
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 229930003827 cannabinoid Natural products 0.000 description 8
- 239000003557 cannabinoid Substances 0.000 description 8
- 229940117948 caryophyllene Drugs 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 7
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 208000028006 Corneal injury Diseases 0.000 description 6
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 6
- YLEARPUNMCCKMP-DOFZRALJSA-N N-arachidonoylglycine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC(O)=O YLEARPUNMCCKMP-DOFZRALJSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 229940023103 lifitegrast ophthalmic solution Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 229940023106 xiidra Drugs 0.000 description 5
- VFTRKSBEFQDZKX-UHFFFAOYSA-N 3,3'-diindolylmethane Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4NC=3)=CNC2=C1 VFTRKSBEFQDZKX-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AWMHMGFGCLBSAY-SFHVURJKSA-N Rutamarin Chemical compound C1=C(C(C)(C)C=C)C(=O)OC2=C1C=C1C[C@@H](C(C)(C)OC(=O)C)OC1=C2 AWMHMGFGCLBSAY-SFHVURJKSA-N 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 4
- NBMMIBNZVQFQEO-UHFFFAOYSA-N (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1C(C)(C)C1(C)C NBMMIBNZVQFQEO-UHFFFAOYSA-N 0.000 description 3
- LJSBBBWQTLXQEN-UHFFFAOYSA-N (2-methyl-1-propyl-3-indolyl)-(1-naphthalenyl)methanone Chemical compound C12=CC=CC=C2N(CCC)C(C)=C1C(=O)C1=CC=CC2=CC=CC=C12 LJSBBBWQTLXQEN-UHFFFAOYSA-N 0.000 description 3
- LJKYKFRQAQCNIN-DOFZRALJSA-N 2-[[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenyl]amino]ethanol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCNCCO LJKYKFRQAQCNIN-DOFZRALJSA-N 0.000 description 3
- CUJUUWXZAQHCNC-DOFZRALJSA-N 2-arachidonyl glyceryl ether Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CO)CO CUJUUWXZAQHCNC-DOFZRALJSA-N 0.000 description 3
- VWVAIBKHFCUSMD-UHFFFAOYSA-N AM2232 Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4N(CCCCC#N)C=3)=O)=CC=CC2=C1 VWVAIBKHFCUSMD-UHFFFAOYSA-N 0.000 description 3
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 description 3
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JDNLPKCAXICMBW-UHFFFAOYSA-N JWH 018 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=CC=C12 JDNLPKCAXICMBW-UHFFFAOYSA-N 0.000 description 3
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LNGVQORPSNNMSZ-UHFFFAOYSA-N [1-(5-fluoropentyl)-6-nitroindol-3-yl]-naphthalen-1-ylmethanone Chemical compound C12=CC=C(N(=O)=O)C=C2N(CCCCCF)C=C1C(=O)C1=CC=CC2=CC=CC=C12 LNGVQORPSNNMSZ-UHFFFAOYSA-N 0.000 description 3
- QGNIEJBBHMMNOZ-UHFFFAOYSA-N [2-methyl-1-[(1-methylpiperidin-2-yl)methyl]-6-nitroindol-3-yl]-naphthalen-1-ylmethanone Chemical compound CN1CCCCC1CN1C2=CC(N(=O)=O)=CC=C2C(C(=O)C=2C3=CC=CC=C3C=CC=2)=C1C QGNIEJBBHMMNOZ-UHFFFAOYSA-N 0.000 description 3
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 3
- 239000000607 artificial tear Substances 0.000 description 3
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 3
- 229960003453 cannabinol Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- IBBNKINXTRKICJ-UHFFFAOYSA-N jwh-007 Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=CC2=CC=CC=C12 IBBNKINXTRKICJ-UHFFFAOYSA-N 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 210000004561 lacrimal apparatus Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004175 meibomian gland Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 2
- ZSCHDSYZOUKNFL-DOFZRALJSA-N (8z,11z,14z,17z)-1,2,3-trihydroxytricosa-8,11,14,17-tetraen-4-one Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(O)C(O)CO ZSCHDSYZOUKNFL-DOFZRALJSA-N 0.000 description 2
- 229940093768 3,3'-diindolylmethane Drugs 0.000 description 2
- 235000010045 3,3'-diindolylmethane Nutrition 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YSBFLLZNALVODA-RBUKOAKNSA-N JWH-133 Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCC)=CC=C3[C@@H]21 YSBFLLZNALVODA-RBUKOAKNSA-N 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 2
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 229920006184 cellulose methylcellulose Polymers 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- JRLHSTVTOOELAF-KRWDZBQOSA-N dehydrofalcarinol Natural products O[C@@H](C=C)C#CC#CCC=CCCCCCC=C JRLHSTVTOOELAF-KRWDZBQOSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000012802 pre-warming Methods 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 229940053174 restasis Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GYDMBTYTWYNRGO-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluorononane Chemical compound CCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)F GYDMBTYTWYNRGO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010053990 Dacryostenosis acquired Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- NPNUFJAVOOONJE-FLFDDASRSA-N Isocaryophyllene Chemical compound C1CC(/C)=C\CCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-FLFDDASRSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 244000016296 Jacobaea maritima Species 0.000 description 1
- 206010023642 Lacrimation decreased Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 229920001046 Nanocellulose Polymers 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YWEZXUNAYVCODW-OALUTQOASA-N abnormal cannabidiol Chemical compound CCCCCC1=CC(O)=CC(O)=C1[C@@H]1[C@H](C(C)=C)CCC(C)=C1 YWEZXUNAYVCODW-OALUTQOASA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 201000008996 filamentary keratitis Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 208000000617 lacrimal duct obstruction Diseases 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960005381 lifitegrast Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- OHIDOYVJPZRAHI-UHFFFAOYSA-N pentanenitrile Chemical compound CC[CH]CC#N OHIDOYVJPZRAHI-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191194.6 | 2016-09-28 | ||
| EP16191194 | 2016-09-28 | ||
| EP17168172 | 2017-04-26 | ||
| EP17168172.9 | 2017-04-26 | ||
| PCT/EP2017/074545 WO2018060282A1 (en) | 2016-09-28 | 2017-09-27 | Compositions comprising a cannabinoid receptor binding ligand |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036313A1 true CA3036313A1 (en) | 2018-04-05 |
Family
ID=59966776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036313A Withdrawn CA3036313A1 (en) | 2016-09-28 | 2017-09-27 | Compositions comprising a cannabinoid receptor binding ligand |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190343793A1 (enExample) |
| EP (2) | EP3518921B1 (enExample) |
| JP (1) | JP2019534867A (enExample) |
| KR (1) | KR20190060787A (enExample) |
| CN (1) | CN109803650A (enExample) |
| AU (1) | AU2017333420A1 (enExample) |
| BR (1) | BR112019006194A2 (enExample) |
| CA (1) | CA3036313A1 (enExample) |
| MX (1) | MX2019003544A (enExample) |
| WO (1) | WO2018060282A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| BR112015005008B1 (pt) | 2012-09-12 | 2022-04-19 | Novaliq Gmbh | Composições de alcano semifluorado |
| CN104619314B (zh) | 2012-09-12 | 2017-09-22 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| CN114028560A (zh) | 2013-07-23 | 2022-02-11 | 诺瓦利克有限责任公司 | 稳定的抗体组合物 |
| CN113662929A (zh) | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| KR102122887B1 (ko) | 2016-05-03 | 2020-06-16 | 뉴마 레스퍼러토리 인코포레이티드 | 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법 |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| KR20190057338A (ko) | 2016-09-23 | 2019-05-28 | 노바리크 게엠베하 | 시클로스포린을 포함하는 안과 조성물 |
| US10732712B2 (en) * | 2016-12-27 | 2020-08-04 | Facebook Technologies, Llc | Large scale integration of haptic devices |
| EP3612228B1 (en) | 2017-04-21 | 2023-08-23 | Dermaliq Therapeutics, Inc. | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| CN118203735A (zh) | 2017-10-04 | 2024-06-18 | 精呼吸股份有限公司 | 电子呼吸致动式直线型液滴输送装置及其使用方法 |
| CA3082192A1 (en) | 2017-11-08 | 2019-05-16 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
| AU2019228119A1 (en) | 2018-03-02 | 2020-09-10 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| IL276888B2 (en) | 2018-03-28 | 2024-12-01 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| EP3784246A1 (en) | 2018-04-27 | 2021-03-03 | Novaliq GmbH | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| CN112823020A (zh) | 2018-10-12 | 2021-05-18 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
| KR102534570B1 (ko) * | 2019-02-01 | 2023-05-18 | 에어리 파마슈티컬즈, 인코포레이티드 | 근시의 치료를 위한 화합물, 조성물 및 방법 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| AU2020340561B2 (en) | 2019-09-06 | 2026-01-22 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| CN115968278A (zh) | 2020-05-18 | 2023-04-14 | 麦氏生物科技有限公司 | 脂质-聚合物组合物及使用方法 |
| CA3173494A1 (en) * | 2020-09-24 | 2022-03-31 | Michael Foster DAVIS | Cannabinoid composition comprising at least 50% carrier |
| US20230405025A1 (en) * | 2020-10-05 | 2023-12-21 | Max Biology Co. Ltd. | Cannabinoid-containing compositions and use for treating and preventing diseases |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| WO2022169788A1 (en) | 2021-02-03 | 2022-08-11 | Ads Therapeutics Llc | Topical ophthalmological compositions |
| WO2022271848A1 (en) | 2021-06-22 | 2022-12-29 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
| EP4415708A4 (en) * | 2021-10-13 | 2025-07-30 | Pneuma Respiratory Inc | COMPOSITIONS FOR THE ADMINISTRATION OF CANNABINOIDS |
| US20260033533A1 (en) | 2022-07-18 | 2026-02-05 | Pneuma Respiratory, Inc. | Small step size and high resolution aerosol generation system and method |
| WO2026037894A1 (en) * | 2024-08-15 | 2026-02-19 | Dermaliq Therapeutics, Inc. | Semifluorinated alkane compositions for cleaning the skin |
| WO2026047389A1 (en) * | 2024-08-30 | 2026-03-05 | Vicadia Lda | Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| EP2046290A4 (en) | 2006-08-04 | 2011-08-17 | Insys Therapeutics Inc | AQUEOUS DRONABINOL FORMULATIONS |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| PL2352497T3 (pl) | 2008-10-31 | 2017-08-31 | University Of Mississippi | Proces przygotowania estrów aminokwasowych delta-9-thc |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| EP2444063A1 (en) * | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| BR112015005008B1 (pt) * | 2012-09-12 | 2022-04-19 | Novaliq Gmbh | Composições de alcano semifluorado |
| CN104619314B (zh) * | 2012-09-12 | 2017-09-22 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| US9265809B2 (en) | 2013-10-09 | 2016-02-23 | Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| ES2784229T3 (es) | 2013-11-20 | 2020-09-23 | Panag Pharma Inc | Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular |
| MA41299A (fr) | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
-
2017
- 2017-09-27 BR BR112019006194A patent/BR112019006194A2/pt not_active IP Right Cessation
- 2017-09-27 CN CN201780058931.9A patent/CN109803650A/zh not_active Withdrawn
- 2017-09-27 EP EP17772438.2A patent/EP3518921B1/en active Active
- 2017-09-27 US US16/337,617 patent/US20190343793A1/en not_active Abandoned
- 2017-09-27 WO PCT/EP2017/074545 patent/WO2018060282A1/en not_active Ceased
- 2017-09-27 JP JP2019516407A patent/JP2019534867A/ja active Pending
- 2017-09-27 EP EP20159519.6A patent/EP3698785A1/en not_active Withdrawn
- 2017-09-27 KR KR1020197010976A patent/KR20190060787A/ko not_active Ceased
- 2017-09-27 AU AU2017333420A patent/AU2017333420A1/en not_active Abandoned
- 2017-09-27 MX MX2019003544A patent/MX2019003544A/es unknown
- 2017-09-27 CA CA3036313A patent/CA3036313A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019006194A2 (pt) | 2019-06-18 |
| KR20190060787A (ko) | 2019-06-03 |
| EP3518921B1 (en) | 2021-08-11 |
| CN109803650A (zh) | 2019-05-24 |
| WO2018060282A1 (en) | 2018-04-05 |
| MX2019003544A (es) | 2019-09-19 |
| AU2017333420A1 (en) | 2019-04-04 |
| JP2019534867A (ja) | 2019-12-05 |
| US20190343793A1 (en) | 2019-11-14 |
| EP3698785A1 (en) | 2020-08-26 |
| EP3518921A1 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3518921B1 (en) | Compositions comprising a cannabinoid receptor binding ligand | |
| DK2512515T3 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DRY EYES | |
| US9937225B2 (en) | Topical formulations and uses thereof | |
| CN112135603B (zh) | 包含奈必洛尔的药物组合物 | |
| HK40036791A (en) | Compositions comprising a cannabinoid receptor binding ligand | |
| HK40008248A (en) | Compositions comprising a cannabinoid receptor binding ligand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AZWI | Withdrawn application |
Effective date: 20220225 |
|
| AZWI | Withdrawn application |
Effective date: 20220225 |